Losartan Inhibits Nuclear Factor-κB Activation Induced by Small, Dense LDL Cholesterol Particles in Human Umbilical Vein Endothelial Cells  by Guo, Gonghui et al.
Current Therapeutic Research 76 (2014) 17–20Contents lists available at ScienceDirectCurrent Therapeutic Research0011-39
http://d
☆This
Commo
mits no
the orig
n Add
People’s
E-mjournal homepage: www.elsevier.com/locate/cuthreLosartan Inhibits Nuclear Factor-κB Activation Induced by Small, Dense
LDL Cholesterol Particles in Human Umbilical Vein Endothelial Cells☆
Gonghui Guo, MM, Xiaojing Cheng, MMn, Rong Fu, MM
Department of Cardiology, The People’s Hospital of Rizhao, Rizhao, Chinaa r t i c l e i n f o
Article history:
Accepted 24 November 2013
Objective: We aimed to investigate how losartan exerts protective effects on human umbilical vein
endothelial cell injury induced by small, dense, LDL (sLDL) cholesterol particles.Key Words:
losartan
nuclear factor-κB
small, dense, LDL3X/$ - see front matter & 2014. The Authors.
x.doi.org/10.1016/j.curtheres.2013.11.006
is an open-access article distributed unde
ns Attribution-NonCommercial-No Derivative
n-commercial use, distribution, and reproduct
inal author and source are credited.
ress correspondence to: Dr. Xiaojing Cheng, D
Hospital of Rizhao, 126 Tai an Rd, Rizhao 27
ail address: tgjmeds@126.com (X. Cheng).a b s t r a c t
Methods: sLDL cholesterol was isolated by a 2-steps method and the nuclear translocation and activation
of nuclear factor-κB (NF-κB) in endothelial cells was observed by confocal microscopy and electrophoretic
mobility shift assays.
Results: Losartan greatly inhibited the nuclear translocation of NF-κB induced by sLDL cholesterol in a
dose-dependent manner.
Conclusions: sLDL cholesterol may be involved in endothelial dysfunction possibly through NF-κB
activation; losartan protects against sLDL cholesterol-inducing endothelial cell injury by inhibiting
NF-κB activation, suggesting that losartan may play a role in the prevention and treatment of
cardiovascular disease.
& 2014. The Authors. Published by Elsevier Inc. All rights reserved.Introduction
During the past 2 decades it has become evident that the
vascular endothelium is an active paracrine, endocrine, and auto-
crine organ that is not only indispensable for the regulation of
vascular tone and blood ﬂow, but also for the maintenance of
vascular homeostasis.1 When endothelial cells get damaged, they
can trigger an inﬂammation response through secretion of inﬂam-
matory factors and regulation of the leukocyte adhesion surface,
which then leads to the initiation and expansion of atherosclerosis
(As).1 So, endothelial dysfunction is thought to be the key event
and the most important risk factor in the process of As.
Endothelial dysfunction has many causes, such as hyperlipide-
mia, hypertension, diabetes, and smoking. Studies have shown that
LDL cholesterol becomes oxidized in response to oxidative stress
and results in the formation of oxidized LDL (ox-LDL) cholesterol.
Ox-LDL cholesterol is a vital factor that can activate nuclear factor-
κB (NF-κB) and increase expression of inﬂammatory factors, such
as adhesion molecule and tissue factors, and then cause endothe-
lial dysfunction.2,3 Small, dense LDL (sLDL) cholesterol is a subclass
of LDL. In recent years, a large number of epidemiologic and
clinical studies have shown the role elevated sLDL levels play inPublished by Elsevier Inc. All right
r the terms of the Creative
Works License, which per-
ion in any medium, provided
epartment of Cardiology, The
6826, China.the initiation of As and that it is a risk factor in coronary heart
disease.4,5
Angiotensin II (AngII), the major effector of the renin-
angiotensin system, also contributes to endothelial dysfunction.6,7
Angiotensin receptor antagonists (ARBs) can antagonize the effect
of AngII at the receptor level, and therefore have been widely used
in clinical practice in the form of antihypertensive drugs. Large-
scale clinical trials have indicated that losartan, a kind of ARB, can
prevent As through down-regulating NF-κB, thus leading to the
inhibition of oxygen free radicals, adhesion molecules, monocyte-
macrophage chemokines, and stromal metalloproteinase.8–11
However, little research is done in China to investigate the
mechanisms of how losartan inhibits As. Here, we report that
losartan can inhibit nuclear translocation of NF-κB induced by sLDL
cholesterol in human umbilical vein endothelial cells, adding to
our understanding about the possible molecular mechanism for
lipid disorders and the independent antihypertensive ways by
which ARBs are involved in anti-As treatment.Materials and Methods
Antibodies and reagents
Losartan used in our study was a gift from Xiuzheng Pharmaceut-
ical Group Company Limited. Edathamil disodium (EDTA) was
acquired from Sigma-Aldrich (Shanghai, China), whereas Dulbecco’s
modiﬁcation of Eagle's medium, Serum, total RNA extraction reagent,
and Trypsin were procured from GIBCO Life Technology Company
(Shanghai, China). Rabbit polyclonal antibodies against p65 weres reserved.
sLDL (diameter≤25.5nm)
Figure 1. The small, dense, LDL (sLDL) cholesterol was isolated and observed by
transmission electron microscope.
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medical Engineering Company (Beijing, China) was the source for α-
32P-deoxycytidine triphosphate.
Isolation and measurement of sLDL cholesterol
The 2-step ultracentrifugation method was used to extract and
separate sLDL cholesterol as described previously.12 This method
consists of 2 steps. The ﬁrst step is to separate sLDL; the second
step is to identify sLDL. Zhong Ke Mai Chen Technology Co Ltd
(Beijing, China) was used to measure the protein concentration of
sLDL cholesterol.
Human umbilical vein endothelial cell culture, identiﬁcation,
and treatment
Human umbilical vein endothelial cells were isolated from freshly
obtained healthy maternal newborn umbilical cords and grown in
tissue culture. Cultured endothelial cells were observed by phase
contrast microscopy and identiﬁed for growth factor-related antigen.
Cells, subcultured for 2–5 passages, were used for experiments. To
examine the effect of losartan on sLDL cholesterol-induced NF-κB
activation, cells were treated with either 100 μg/mL sLDL cholesterol
or with different concentrations of losartan (10–7, 10–6, or 10–5 mol/L)
plus 100 g/mL sLDL cholesterol. In the losartan interference experi-
ment, cells were ﬁrst incubated with losartan for 2 hours, and then
sLDL cholesterol (100 g/mL) was added. Tumor necrosis factor-α
(TNF-α) (200 U/mL) treatment was used as a positive control.
Preparation of nuclear extracts
Nuclear extracts were isolated as described previously.13
Brieﬂy, cells were washed with ice-cold phosphate-buffered saline
(PBS) and pelleted, and then the cell pellet was resuspended in a
hypotonic buffer (10 mM N-2-hydroxyethylpiperazine-N-2-
ethane sulfonic acid [HEPES], pH 7.9, 10 mM potassium chloride,
0.1 mM EDTA, 0.1 mM ethylene glycol tetraacetic acid [EGTA],
1 mM dithiothreitol [DTT], 0.5 mM phenylmethylsulfonyl ﬂuoride
[PMSF], 1 mM sodium ﬂuoride, and 1 mM sodium orthovandate),
incubated for 15 minutes on ice, and then lysed by the addition of
0.5% octylphenoxypolyethoxyethanol followed by vigorous vor-
texing for 10 seconds. The nuclei were pelleted and resuspended
in extraction buffer (20 mM HEPES, pH 7.9, 400 mM sodium
chloride, 1 mM EDTA, 1 mM EGTA, 1 mM DTT, 1 mM PMSF, 1 mM
sodium ﬂuoride, and 1 mM sodium orthovandate), and the tube
was vigorously shaken at 41C for 15 minutes on a shaking plat-
form. The nuclear extracts were then centrifuged, and the super-
natants were aliquoted and stored at –801C. Protein concen-
trations can be determined according to the method of Bradford
(BioRad, Veenendaal, the Netherlands).
Fluorescence confocal microscopy
Endothelial cells were treated with appropriate stimulus. After
treatment for 24 hours, cells were ﬁxed in 4% paraformaldehyde for
10 minutes followed by incubation in 0.5% polyethylene glycol
octylphenol in PBS for 10 minutes for permeabilization, and were
blocked with 10% goat serum in PBS for 1 hour. Cells were then
incubated for 1 hour in 1:100 diluted solution of anti-p65-antibody
in 10% goat serum followed by several washes and incubation in
1:100 solution of the secondary antibody ﬂuorescein-goat-anti-rabbit
immunoglobulin G for the detection of p65 protein. Washed cells
were mounted in Vecta Shield (Vector Laboratories, Burlingame,
California) containing 0.1 μg/mL 40, 6-diamidino-2-phenylindole to
stain nuclei. FV-REVIEW STATI10N software was used to determine
the relative amount of p65 translocation.Electrophoretic Mobility Shift Assay (EMSA)
EMSAs were performed by incubating 14 μg nuclear extract
with 20 fmol of the 32P-end-labeled NF-κB consensus oligonu-
cleotide 50-CGCTTGATGAGTCAGCCGGAA-30 (Promega, Madison,
Wisconsin) for 15 minutes at 371C. The incubation mixture
included 2–3 μg poly-deoxy-inosinic-deoxy-cytidylic acid in a
binding buffer (25 mM HEPES [pH 7.9], 0.5 mM EDTA, 0.5 mM
DTT, 1% octylphenoxypolyethoxyethanol 5% glycerol, and 50 mM
sodium chloride). The DNA-protein complex thus formed was
separated from free oligonucleotide on 7.5% native polyacrylamide
gel, using buffer containing 50 mM tris(hydroxymethyl)amino-
methane, 200 mM glycine (pH 8.5), and 1 mM EDTA. The gel was
dried, and the radioactive bands were visualized and quantiﬁed by
a PhosphorImager (Molecular Dynamics, Sunnyvale, California),
using ImageQuant software. The speciﬁcity of the NF-κB band was
conﬁrmed by using antibodies against p65 protein.
Statistics
SPSS version 10.0 software (1999, IBM-SPSS, Inc, Armonk, New
York) was used to establish a database. Pairwise comparisons is
done by using independent samples t test, and all experimental
data are expressed as mean (SEM).Results
Isolation and identiﬁcation of sLDL cholesterol
The LDL cholesterol, which was obtained ﬁrstly by centrifuga-
tion, was then separated by ultracentrifugation from plasma. sLDL
cholesterol was isolated (density ¼ 1.044–1.066 g/mL), negatively
stained, and observed. A transmission electron microscope was
used to measure particle size and the result showed that all
particles were o25.5 nm (Figure 1). Thus, our method is reliable
and the sLDL cholesterol that was isolated with this method can be
used for the following study.
Losartan inhibits the nuclear translocation of NF-κB induced by
sLDL cholesterol
To test the effect of losartan on the p65 translocation induced
by sLDL cholesterol in endothelial cells, immunostaining of p65
was performed in the presence or absence of sLDL cholesterol. As
show in Figure 2A, without sLDL cholesterol, p65 was mainly
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Figure 2. Losartan inhibits the nuclear translocation of nuclear factor-κB (NF-κB)
induced by small, dense LDL (sLDL) cholesterol particles. (A) Subcellular localization
of p65 under different stimulus. Endothelial cells were treated with 200 U/mL
tumor necrosis factor-α (TNF-α), 100 μg/mL sLDL cholesterol, or 100 μg/mL sLDL
cholesterol plus different concentrations of losartan (10–7 mol/L, 10–6 mol/L, or
10–5 mol/L). Twenty-four hours after incubation, rhodamine staining of p65 was
visualized by ﬂuorescence microscopy. (B) Semiquantitative analysis of p65 trans-
location. Endothelial cells were treated with 200 U/mL TNF-α, 100 μg/mL sLDL, or
100 μg/mL sLDL plus different concentrations of losartan (10–7 mol/L, 10–6 mol/L, or
10–5 mol/L). Twenty-four hours after incubation, subcellular distribution of p65 was
scored in at least 10 cells. The results are means (SD) of 3 independent determina-
tions. (C) Endothelial cells were exposed to different stimuli; nuclear extracts were
made and analyzed with electrophoretic mobility shift assay as described in the
text. A representative blot presented here shows that sLDL cholesterol (50 μg/mL,
100 μg/mL, and 150 μg/mL) activates NF-κB in a dose-dependent manner (lanes 2–
5). Losartan (10–7 mol/L, 10–6 mol/L, and 10–5 mol/L) can inhibit the sLDL
cholesterol-induced NF-κB activation in a dose-dependent manner (lanes 7–9).
Treatment with 200 U/mL TNF-α was used a positive control (lane 6).
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positive control. Under sLDL stimulation, p65 translocated to the
nucleus. Compared with control cells, losartan can inhibit thetranslocation of p65 in dose-dependent fashion. Semiquantitative
analysis was also performed (Figure 2B). Moreover, EMSA analysis
conﬁrmed our results (Figure 2C). These data support a notion
that losartan inhibits the nuclear translocation of NF-κB induced
by sLDL cholesterol in a dose-dependent manner.Discussion
The LDL cholesterol in plasma is made up of particles of
unequal size and density. By density gradient ultracentrifugation
or nondenaturing gradient gel method, the particles can be
divided into many subclasses, mainly 3 types: low-density, larger
size particles; intermediate-density, median size particles (LDL);
and high-density, smaller size particles (sLDL). In recent years, a
large number of epidemiologic and clinical studies have indicated
that an increased proportion of sLDL cholesterol in total LDL
cholesterol levels plays an important role in the occurrence of
As, which is a risk factor for coronary heart disease.14–16 The
generally acknowledged mechanisms that lead to As are the fact
that sLDL cholesterol particles more readily permeate the inner
arterial wall and deposit in the arterial intima, and that reducing
acylneuraminate in the surface of sLDL cholesterol leads to the
decrease of polyanion and more combination with proteoglycan in
the arterial wall. Thus, sLDL cholesterol adheres to arterial walls
and gives rise to the deposition of cholesterol; the spatial con-
formation of apolipoprotein B is not easily combined with the
plasma LDL cholesterol receptor; therefore, the plasma LDL cho-
lesterol receptor removal pathway is not efﬁcient. Due to the
reduction of free cholesterol in the lipid layer of sLDL cholesterol
surface and increase of polyunsaturated acid, sLDL cholesterol can
be easily oxidized and taken advantage by macrophages to form
foam cells. Therefore, sLDL cholesterol is a pathogenic factor for As,
and it will become 1 of the indicators that predicts As disease.
Because it is characterized by chronic inﬂammation and the
hyperplasia process, As may be a NF-κB-mediated chronic inﬂam-
matory disease.17 It is reported that NF-κB is involved in the
regulation of many intercellular gene expressions that are related
to As (including the expression of vascular cell adhesion molecule-1
and intercellular adhesion molecule-1), promotes the local adhesion
of monocytes and their migration to atherosclerotic injury predi-
lection sites,18 and thus participates in the occurrence and develop-
ment of As. Moreover, studies showed that ox-LDL increases
expression of adhesion molecules, decreases NF-κB activity, inhibits
the upregulation of adhesion molecules, prevents the formation of
foam cells, and slows the progress of As.19,20 Therefore, all these
studies suggest that NF-κB can regulate the expression of adhesion
molecules and play an important role in the pathogenesis of As.
In our study, in the absence of losartan, NF-κB was signiﬁcantly
accumulated in the nucleus with sLDL cholesterol stimulation. In
the presence of losartan, however, the sLDL-stimulated accumu-
lation of NF-κB in the nucleus was greatly inhibited. This result
was conﬁrmed by EMSA. These experiments indicate that sLDL can
be involved in the initiation and progression of atherosclerosis,
possibly through releasing of inﬂammatory cytokines that were
caused by activation of NF-κB, whereas losartan can prevent the
progress of As by inhibiting the activation of NF-κB. sLDL has also
been reported to affect human umbilical vein endothelial cells and
enhance the activity of activated protein-1.16 In addition, AngII
may also participate in the regulation of As-related genes, possibly
through regulation of some important transcription factors, such
as speciﬁcity protein-1 and activated protein-1, in human umbil-
ical vein endothelial cells.8 Therefore, future investigations will
need to address whether or not sLDL cholesterol inﬂuences the
damage effect through other transcription factors and if losartan
protects endothelial cells by other mechanisms.
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